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Abstract
MicroRNAs (miRNAs) are attractive molecules to utilize as one of the blood-based biomarkers for neurodegenerative
disorders such as Alzheimer’s disease (AD) because miRNAs are relatively stable in biofluid, including serum or
plasma. To determine blood miRNA biomarkers for AD with next-generation sequencing genome-wide, we first
surveyed 45 serum samples. These came from 27 AD patients and 18 controls (discovery set) that underwent
autopsy within two weeks after their serum sampling and were neuropathologically diagnosed. We found that
three miRNAs, hsa-miR-501-3p, hsa-let-7f-5p, and hsa-miR-26b-5p, were significantly deregulated between the
AD samples and the controls. The deregulation for hsa-miR-501-3p was further confirmed by quantitative reverse
transcription polymerase chain reaction (PCR) in a validation set composed of 36 clinically diagnosed AD patients
and 22 age-matched cognitively normal controls with a sensitivity and specificity of 53% and 100%, respectively
(area under the curve = 0.82). Serum hsa-miR-501-3p levels were downregulated in AD patients, and its lower levels
significantly correlated with lower Mini-Mental State Examination scores. Contrary to its serum levels, we found that
hsa-miR-501-3p was remarkably upregulated in the same donors’ AD brains obtained at autopsy from the discovery
set. The hsa-miR-501-3p overexpression in cultured cells, which mimicked the hsa-miR-501-3p upregulation in
the AD brains, induced significant downregulation of 128 genes that overrepresented the Gene Ontology terms,
DNA replication, and the mitotic cell cycle. Our results suggest that hsa-miR-501-3p is a novel serum biomarker
that presumably corresponds to pathological events occurring in AD brains.
Keywords: Alzheimer’s disease, Blood-based biomarker, microRNA, miR-501-3p, Next-generation sequencing,
Autopsied brain, Braak staging
Introduction
Alzheimer’s disease (AD) is the most common form of
dementia in the elderly and is characterized by two
neuropathological hallmarks: extracellular senile plaques (SPs),
composed of β-amyloid (Aβ) peptides, and intraneuronal
neurofibrillary tangles (NFTs) composed of abnor-
mally hyperphosphorylated tau. To facilitate the clin-
ical diagnosis of AD, numerous studies have focused on
biomarkers based on neuroimaging and molecules in
cerebrospinal fluid (CSF) and peripheral blood. For
example, neuroimaging using positron emission tomog-
raphy with the tracer carbon-11-labeled Pittsburgh
compound B can detect Aβ deposits in the brains of living
subjects. However, neuroimaging tests are expensive and
available at only a limited number of laboratories. As a
result, access to neuroimaging is confined to a small
number of patients. Similarly, Aβ and tau protein levels in
CSF are well-established biomarkers with high accuracy
for AD [8, 15], but CSF sampling by lumbar puncture is
relatively invasive and requires skilled training. In
contrast, blood sampling is less invasive and available at
routine examinations. Once useful blood-based bio-
markers are established, they allow physicians to screen a
larger number of subjects. Recent studies have reported
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potential blood-based biomarkers for AD from various
molecular species, such as protein, lipid, and nucleic
acid [23].
MicroRNA (miRNA) is considered one of the candi-
dates for blood-based biomarkers. miRNAs are ~22 nt
small noncoding RNAs that bind to the 3′ untranslated
region of their target mRNAs to direct posttranscrip-
tional repression of the target genes by forming the
RNA-induced silencing complex, which leads to mRNA
destabilization or translational inhibition [5, 6]. Some
miRNAs are encapsulated in microvesicles, such as
exosomes, and present as a relatively stable form in
biofluid, including serum or plasma [39]. Recently, some
sets of blood miRNAs have been shown to differentiate
AD or mild cognitive impairment (MCI) from healthy
controls [12, 21, 28, 32, 36, 42, 45]. For example, plasma
levels of the miR-132 family (miR-128, miR-132, and
miR-874) have distinguished MCI from age-matched
controls with high accuracy (84–94% sensitivity and
96–98% specificity) [42]. In addition, alterations of
miRNAs have also been observed in AD brains [20, 22,
41]. Hébert et al. have shown that in AD brains the
miR-29a/b-1 cluster levels are decreased and correlated
with the high BACE1 expression that leads to Aβ gener-
ation, suggesting that these miRNAs directly regulate
the BACE1 gene expression [22]. Despite the increasing
evidence of miRNAs for AD pathology, their relationship
between peripheral blood levels and brain levels, espe-
cially in the same individuals, is largely unexplored.
Here, we identified hsa-miR-501-3p as a novel serum
miRNA biomarker that was downregulated in AD
patients. We measured hsa-miR-501-3p levels in the
same donors’ brains that were obtained at autopsy
within two weeks after their serum sampling and found
remarkable upregulation of hsa-miR-501-3p. To eluci-
date the effects of the hsa-miR-501-3p upregulation in
the AD brains, we performed hsa-miR-501-3p overex-
pression analysis in cultured cells.
Materials and methods
Subjects
We prepared two independent sample sets to discover
and validate potential serum miRNA biomarkers for AD.
The discovery set, ROW, consisted of samples obtained
from the Japanese Brain Bank Network for Neuroscience
Research (JBBNNR), where all autopsied brains are
systematically diagnosed with Braak staging [10, 11] and
stored at −80 °C. We used serum that was collected
from donors in routine blood tests within two weeks
before their death. The temporal cortex tissues from the
same donors were dissected by experts at JBBNNR and
stored at −80 °C until use.
The validation set, NIG, was composed of clinically
diagnosed subjects from Niigata University Medical and
Dental Hospital. The diagnosis of AD was made by the
criteria of the National Institute of Neurological and
Communicative Diseases and the Stroke–Alzheimer’s
Disease and Related Disorders Association [38]. Serum
was collected from the subjects during the clinical
follow-up period in the outpatient department and
stored at −80 °C until analysis.
APOE genotyping
Isolation of genomic DNA from brain or blood samples
and APOE genotyping were performed as previously
described [29].
RNA extraction
Cell-free RNA was isolated from 200 μl of serum with
miRNeasy Serum/Plasma Kit (QIAGEN, Hilden,
Germany). For quantitative reverse transcription PCR
(qRT-PCR) assay of the NIG validation set, 5.6 × 108
copies of synthetic cel-miR-39-3p (miRNeasy Serum/
Plasma Spike-In Control; QIAGEN) were added to each
serum sample to normalize and monitor extraction effi-
ciency. Finally, serum RNA was eluted in 14 μl of
RNase-free water.
Total RNA was isolated from a small piece of the fro-
zen temporal cortex tissue or cultured cells with TRIzol
Plus RNA Purification Kit (Thermo Fisher Scientific,
Waltham, MA, USA). The isolated total RNA was
loaded on the Agilent 2100 Bioanalyzer instrument
(Agilent Technologies, Santa Clara, CA, USA) to deter-
mine the value of the RNA integrity number (RIN),
which indicates the quality of mRNA transcripts and
ranges from 1 (totally degraded) to 10 (intact).
Small RNA sequencing
We prepared small RNA sequencing libraries with the
TruSeq Small RNA Sample Prep Kit (Illumina, San
Diego, CA, USA), using 1 μg of total RNA or 5 μl of the
14 μl purified serum RNA as input. Each library was se-
quenced on Illumina Genome Analyzer IIx (GAIIx), and
more than 20,000,000 single-end reads were obtained
from each library. Adapter sequences were trimmed
from the sequenced reads with cutadapt [37], and then
the reads were mapped using bowtie [30] against the
human genome build hg19. The number of mapped
reads was counted using HTSeq [3] in each miRNA
from miRBase release 20 [26]. The raw read counts were
normalized by the median-of-ratios method imple-
mented in DESeq2 [35]. To remove low-abundance
miRNAs, we filtered out miRNAs with <50 mean nor-
malized read counts across all samples. We used DESeq2
[35] to identify deregulated miRNAs between AD and
controls. We also performed differential miRNA expression
analysis with DESeq2’s design formula including the add-
itional covariates, age, sex, APOE genotype, and hemolysis
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ratio or RIN, to adjust for these variables. P-values were cal-
culated by the Wald test and adjusted by the Benjamini–
Hochberg procedure [7] for multiple testing correction. We
considered miRNAs with <0.05 adjusted p-value (5% false
discovery rate (FDR)) statistically significant.
Evaluation of hemolysis
To detect the degree of hemolysis during serum prepar-
ation, free hemoglobin levels were measured spectro-
photometrically. 12 μl of serum was diluted with 48 μl
of phosphate buffered saline and then used to determine
the ratio of the absorbance at 414 nm and 375 nm,
hemolysis ratio (A414/375), whose higher values show
hemolyzed samples [25, 49]. We removed serum samples
with >2 hemolysis ratio from the NIG validation set.
qRT-PCR
Candidate serum miRNAs were validated by qRT-PCR
using TaqMan MicroRNA Assays (Thermo Fisher
Scientific). 5 μl of serum RNA was reverse transcribed to
cDNA with the TaqMan MicroRNA Reverse Transcription
kit using an RT primer pool containing three target
miRNA primers (hsa-miR-501-3p, hsa-let-7f-5p, and
hsa-miR-26b-5p) and two normalization miRNA primers
(cel-miR-39-3p and hsa-miR-451a) at a final concentration
of 0.2 × each in a reaction volume of 15 μl. 5 μl of the RT
product was preamplified for 12 cycles with TaqMan
PreAmp Master Mix using a preamplification primer pool
containing those five miRNA primers at a final concentra-
tion of 0.03 × each in a reaction volume of 25 μl. The
preamplified product was diluted by adding 100 μl of
0.1 × TE. Using 5 μl of the diluted product, qPCR was
performed in triplicate in a reaction volume of 20 μl
in a 384-well plate on an ABI PRISM 7900HT instru-
ment with TaqMan MicroRNA Assays for each miRNA.
Relative expression levels of miRNAs were calculated by
the 2–ΔΔC T method [34] using cel-miR-39-3p (spike-in)
and hsa-miR-451a (endogenous control) for normalization.
Cell culture and miRNA transfection
A human neuroblastoma cell line of SH-SY5Y cells was
cultured in a 1:1 mixture of minimum essential medium
and Ham’s F-12 nutrient mixture supplemented with
10% fetal bovine serum and 1% penicillin–streptomycin
in a CO2 incubator. One day after seeding, the cells
were transfected with either hsa-miR-501-3p mimic
(MC12927; Thermo Fisher Scientific) or scramble
control (mirVana™ miRNA Mimic, Negative Control #1;
Thermo Fisher Scientific) at 50 nM final concentration
using NeuroMag (OZ Biosciences, San Diego, CA,
USA). After 24 h, the cells were treated with the TRIzol
reagent and stored at −80 °C until RNA extraction.
mRNA sequencing and gene ontology analysis
mRNA sequencing libraries were prepared using TruSeq
RNA Sample Prep Kit v2 (Illumina) with 500 ng of total
RNA as input. Each library was sequenced on GAIIx,
and approximately 40,000,000 of 75 bp single-end reads
were obtained from each library. The sequenced reads
were mapped using STAR [18] against the human
genome (hg19). We used DESeq2 [35] to perform differ-
ential gene expression analysis and considered genes
with <0.05 adjusted p-value (5% FDR) statistically signifi-
cant. We used DAVID 6.8 [16, 17] to perform Gene
Ontology enrichment analysis on significantly differen-
tially expressed genes, focusing on Gene Ontology
category GOTERM_BP_DIRECT. We set the statistical
significance threshold at 0.05 (5% FDR).
Results
Discovery of candidate serum miRNA biomarkers for AD
To prepare the ROW discovery set, we deliberately se-
lected cases whose autopsied brain and serum samples
alike were archived in JBBNNR. According to Braak sta-
ging [10, 11], we defined cases with Braak NFT stages IV
through VI and Braak amyloid stage C as AD, and cases
with Braak NFT stages 0 through II and Braak amyloid
stage 0 or A as controls (Additional file 1: Figure S1) [40].
These definitions of AD and controls prevented the study
sample from including transient forms of the disease (e.g.,
cases with Braak NFT stage III) so that we could distinctly
detect the difference between patients with typical AD
and controls without obvious pathological findings. As a
result, 27 neuropathologically diagnosed AD patients and
18 control subjects were selected. The ROW discovery set
had significant differences (P < 0.05) in age at death, sex,
brain weight, and RIN between AD and controls (Table 1).
We isolated cell-free RNA from serum collected
from the donors within two weeks before their death.
The serum RNA was analyzed by high-throughput next-
generation sequencing (NGS) to compare miRNA levels
between AD and controls. We filtered out low-abundance
miRNAs by mean normalized read counts. Of the
remaining 148 miRNAs, 3 miRNAs had significant
changes in expression level: hsa-miR-501-3p (adjusted
P = 0.002, log2 fold change = −1.58), hsa-let-7f-5p (ad-
justed P = 0.026, log2 fold change = 1.00), and hsa-
miR-26b-5p (adjusted P = 0.026, log2 fold change =
0.93). In the AD patients, hsa-miR-501-3p was down-
regulated and the other two were upregulated (Fig. 1a).
In particular, hsa-miR-501-3p still had a significant
change in expression level after adjusting for age, sex,
APOE genotype, and hemolysis ratio (adjusted P =
0.004, log2 fold change = −2.07; Additional file 2:
Table S1). We added the hemolysis ratio of serum
samples to those covariates because hemolysis could
affect some miRNAs’ levels [25].
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Validation of candidate serum miRNAs
To validate the three candidate serum miRNAs, we
prepared sample set NIG, which was composed of 36
clinically diagnosed AD patients and 22 age-matched
cognitively normal controls (Table 1). Serum was col-
lected from those subjects and examined for the degree
of hemolysis in the same way as the ROW discovery set.
To evaluate more strictly the miRNA levels, we excluded
the serum samples with a >2 hemolysis ratio from the
NIG validation set according to Zanutto et al. [49]. Cell-
free RNA was isolated from the nonhemolyzed serum
samples and analyzed by qRT-PCR to quantify the miRNA
levels. The qRT-PCR analysis revealed that hsa-miR-501-
3p had a significant, consistent change in expression level
(P = 0.00002, log2 fold change = −0.54; Fig. 1b), whereas
hsa-miR-26b-5p showed marginal significance (P = 0.066,
log2 fold change = 0.20; Fig. 1b). Furthermore, serum hsa-
miR-501-3p levels significantly correlated with Mini-
Mental State Examination scores (r = 0.375, P = 0.007;
Fig. 1c). The receiver-operating characteristic curve of
hsa-miR-501-3p showed 53% sensitivity and 100% specifi-
city (area under the curve = 0.82; Fig. 1d). These results
suggest that hsa-miR-501-3p could be a novel serum bio-
marker for clinical diagnosis of AD.
Deregulated hsa-miR-501-3p in AD brains
To investigate whether serum hsa-miR-501-3p levels had
an association with brain levels, we measured hsa-miR-
501-3p levels in the same donors’ brains that were ob-
tained at autopsy within two weeks after their serum
sampling. We used those autopsied brains in the ROW
discovery set and isolated total RNA from their temporal
cortex, a brain region that is severely affected in the late
stages of AD progression [11]. The total RNA was ana-
lyzed by NGS to compare miRNA levels between AD and
controls. The NGS analysis revealed that 187 of 472 miR-
NAs were significantly deregulated (adjusted P < 0.05;
Additional file 2: Table S2). This included hsa-miR-501-
3p, which was prominently upregulated in the AD brains
and had the third lowest p-value (adjusted P = 2.9.E–08,
log2 fold change = 1.98, rank = 3; Fig. 2a and Additional
file 2: Table S2). We found that hsa-miR-501-3p still had a
significant change in expression level after adjusting for
age, sex, APOE genotype, and RIN (adjusted P = 0.0008,
log2 fold change = 1.33, rank = 25; Additional file 2: Table
S3). Moreover, hsa-miR-501-3p levels significantly
correlated with Braak NFT stages (Fig. 2b). As AD
pathology progressed, brain hsa-miR-501-3p levels in-
creased (r = 0.436, P = 0.003) while its serum levels
decreased (r = −0.355, P = 0.017). We also observed
the negative correlation between brain hsa-miR-501-
3p levels and serum hsa-miR-501-3p levels in the
same individuals, although it was not significant (r =
−0.17, P = 0.25; Fig. 2c). Collectively, hsa-miR-501-3p
was deregulated in the brain as well as in the serum
of the same individuals during AD progression.
Functional assays of hsa-miR-501-3p in cultured cells
To elucidate the effects of the hsa-miR-501-3p upregula-
tion in AD brains, we transfected synthetic hsa-miR-
501-3p into SH-SY5Y cells. Total RNA isolated from the
cultured cells was analyzed by NGS to identify genes
that are regulated by hsa-miR-501-3p. Overexpression of
hsa-miR-501-3p in SH-SY5Y cells resulted in significant
changes in the expression levels of 208 genes in com-
parison to the scramble control (adjusted P < 0.05;
Additional file 2: Table S4). Of the 208 significant genes,
128 were downregulated in hsa-miR-501-3p overexpres-
sion. To investigate whether hsa-miR-501-3p directly re-
presses the gene expression of those downregulated
Table 1 Demographics of the two sample sets in this study
CT AD P-value
ROW discovery set
N 18 27 -
AAD, yr 76.3 ± 7.1 84.5 ± 8.0 0.001a
Gender, % (F : M) 27.8 : 72.2 63.0 : 37.0 0.033b
PMI, hr 9.6 ± 9.4 13.4 ± 11.6 0.158a
BW, g 1268 ± 127 1156 ± 120 0.003a
RIN
TC 7.9 ± 0.8 7.1 ± 1.2 0.006a
Hemolysis ratio
Serum 1.9 ± 0.6 1.7 ± 0.5 0.105a
APOE
Genotype, %
(ε3*3 : ε3*4 : ε4*4)
55.6 : 44.4 : 0.0 44.4 : 25.9 : 29.6 0.550c
Allele, % (ε3 : ε4) 77.8 : 22.2 57.4 : 42.6 0.069c
NIG validation set
N 22 36 -
AAE, yr 73.7 ± 8.4 74.7 ± 7.3 0.556a
Gender, % (F : M) 80.0 : 20.0 63.9 : 36.1 0.333b
MMSE 29.3 ± 0.7 19.3 ± 5.4 4.8.E-08a
Hemolysis ratio




85.7 : 14.3 55.6 : 44.4 0.056c
Allele, % (ε3 : ε4) 92.9 : 7.1 77.8 : 22.2 0.090c
Abbreviations: AAD age at death, AAE age at examination, AD Alzheimer’s
disease, APOE apolipoprotein E, BW brain weight, CT control, F female, g
grams, hr hours, M male, MMSE mini-mental state examination, PMI postmortem
interval, RIN RNA integrity number, TC temporal cortex, yr years
aCalculated by Mann-Whitney U-test between AD and CT
bCalculated by Fisher’s exact test for gender distribution
cCalculated by Fisher’s exact test for APOE ε4 allele carrier status (ε4 carrier
and ε4 non-carrier)
Data are presented as the mean ± standard deviation
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genes we used TargetScan 7.1, a database of predictive
targets of each miRNA [2]. Of the 128 downregulated
genes, 123 were annotated by TargetScan 7.1, which
predicted that hsa-miR-501-3p bound to 71 of the 123
genes (71/123 (58%)). This rate of predictive targets of
hsa-miR-501-3p was significantly higher than that of all
the genes tested and annotated by TargetScan 7.1 (1788/
11483 (16%), Fisher’s exact test, P < 9.7.E–16), support-
ing that hsa-miR-501-3p overexpression successfully in-











































































Fig. 1 A novel serum miRNA biomarker hsa-miR-501-3p that differentiates patients with Alzheimer’s disease (AD) from controls (CT). a Serum
miRNA levels of the three candidates significantly deregulated between AD and controls in the ROW discovery set. Normalized read counts from
next-generation sequencing data were converted to a log2 scale and plotted against the disease status. The lower hinge, the line in the middle, and
the upper hinge of the box plot show the 25th percentile, 50th percentile (median), and 75th percentile, respectively. The lower whisker extends from
the lower hinge to the lowest value that is within 1.5 times the interquartile range (IQR) of the hinge. The upper whisker extends from the upper hinge
to the highest value that is within 1.5 times the IQR. LFC: log2 fold change; P: p-value adjusted by the Benjamini–Hochberg procedure for multiple
testing correction. b Three candidates’ serum miRNA levels quantified by quantitative reverse transcription PCR (qRT-PCR) in the NIG validation set.
Relative expression levels of the miRNAs were calculated using the 2–ΔΔC T method with cel-miR-39-3p (spike-in) and hsa-miR-451a (endogenous
control) for normalization and were plotted against the disease status. P-values were computed using the Mann–Whitney U-test between AD and
controls. Box plots display the distributions of data in the same way as in Fig. 1a. LFC: log2 fold change. c Significant positive correlation between Mini-
Mental State Examination (MMSE) scores and serum hsa-miR-501-3p levels in the NIG validation set. Relative expression levels from the qRT-PCR data
were plotted against MMSE. r shows the Spearman rank correlation coefficient. The blue line shows a linear regression line, and a shaded gray area
around the line represents 95% confidence intervals. d The receiver-operating characteristic (ROC) curve of serum hsa-miR-501-3p in the NIG validation
set. The ROC curve analysis showed 53% sensitivity and 100% specificity. The area under the ROC curve (AUC) was 0.82
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cells. To uncover the biological function of the genes
that were altered in hsa-miR-501-3p overexpression, we
used DAVID 6.8 [16, 17] to perform Gene Ontology en-
richment analysis on the 208 significant genes. DAVID
6.8 revealed that the set of the 128 downregulated genes
significantly overrepresented some terms of Gene Ontol-
ogy, such as DNA replication and mitotic cell cycle
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Fig. 2 Deregulated hsa-miR-501-3p not only in the serum but also in the brain of the same individuals over the course of Alzheimer’s disease
(AD) progression. a Brain hsa-miR-501-3p levels prominently upregulated in the AD brains of the ROW discovery set. The levels of hsa-miR-501-3p
in the temporal cortex were analyzed using next-generation sequencing (NGS). Normalized read counts from the NGS data were converted to a
log2 scale and plotted against the disease status. Box plots display the distributions of data in the same way as in Fig. 1a. CT: control; LFC: log2 fold
change; P: p-value adjusted by the Benjamini–Hochberg procedure for multiple testing correction; TC: temporal cortex. b Significant correlation of
either serum hsa-miR-501-3p levels or brain hsa-miR-501-3p levels with Braak NFT stages in the ROW discovery set. While serum hsa-miR-501-3p levels
negatively correlated with Braak NFT stages (Spearman’s r = −0.355, P = 0.017), brain hsa-miR-501-3p levels positively correlated with Braak NFT stages
(Spearman’s r = 0.436, P = 0.003). Normalized read counts from the NGS data were converted to a log2 scale and plotted against Braak NFT stages. Each
thick bar shows the mean value of hsa-miR-501-3p levels in a Braak NFT stage. Each error bar shows a 95% confidence interval of hsa-miR-501-3p levels
in a Braak NFT stage. TC: temporal cortex. c Negative correlation between serum hsa-miR-501-3p levels and brain hsa-miR-501-3p levels in the same
individuals of the ROW discovery set. The levels of hsa-miR-501-3p between serum and brain of the same individuals were insignificantly yet negatively
correlated (Spearman’s r = −0.17, P = 0.25). Normalized read counts of hsa-miR-501-3p levels were converted to a log2 scale and plotted. The x-axis and
y-axis show serum hsa-miR-501-3p levels and brain hsa-miR-501-3p levels, respectively. The blue line shows a linear regression line, and a shaded gray
area around the line represents 95% confidence intervals. Red circles and blue circles show the hsa-miR-501-3p levels of AD patients and control
subjects, respectively. CT: control; TC: temporal cortex
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was observed in the remaining 80 upregulated genes
(Additional file 2: Table S6).
Discussion
There is a significant link between the developments of
SPs and NFTs in the brain and the alterations of Aβ and
tau protein levels in CSF, thus making CSF levels useful
biomarkers that facilitate clinical diagnosis of AD. In this
study, we found that serum hsa-miR-501-3p levels were
downregulated while brain levels were prominently up-
regulated in the AD patients of the ROW discovery set.
Both serum and brain hsa-miR-501-3p levels signifi-
cantly correlated with Braak NFT stages, suggesting that
those hsa-miR-501-3p levels are related to the disease
progression. In addition, the alteration of serum hsa-
miR-501-3p was replicated in the NIG validation set
composed of clinical samples. These results indicate that
serum hsa-miR-501-3p is a plausible biomarker for AD
and its serum levels presumably correspond to its brain
levels, which links to AD pathology. There was up to a
two-week time lag between the serum sampling and
brain autopsy in the ROW discovery set, but a time of
two weeks lends little difference according to the gradual
progression of AD pathology over years. Therefore, we
consider our serum and brain samples in the ROW
discovery set to be collected from each donor at
approximately the same time point.
To our knowledge, alteration of hsa-miR-501-3p in
peripheral blood has never been reported in preceding
AD biomarker studies. This is probably due to technical
differences, including different methods of RNA extrac-
tion [14, 33], different quantitative techniques [47], and
different sources as input such as plasma, serum, and
whole blood. For instance, miRNA contents from blood
cells are much greater than those from cell-free plasma
or serum [47]. Hence, whole blood samples or highly
hemolyzed samples including contaminants of blood
cells may result in outcomes different from serum or
plasma samples. In fact, we discovered hsa-let-7f-5p and
hsa-miR-26b-5p that were upregulated in serum,
whereas Leidinger et al. [32] have reported decreased
levels in whole blood from AD patients. The different
starting materials, namely serum or whole blood, may
lead to the inconsistent results. Consequently, it is vital
to follow a standardized protocol stringently to achieve a
consensus on miRNA biomarkers.
Few studies have described the deregulation of hsa-
miR-501-3p in AD brains as well as peripheral blood.
This may be attributed to the difference in Braak NFT
stages of autopsied brain samples. Our NGS analysis in
the ROW discovery set showed that brain hsa-miR-501-
3p levels did not continuously rise over the Braak NFT
stages; its levels temporarily dropped in Braak NFT stage
V (Fig. 2b). Thus, which Braak NFT stages researchers
define for AD and controls can determine the outcome
of a study. However, the NGS analysis revealed the de-
regulation of miRNAs that other studies have described
(e.g., miR-107 [46], miR-125b [4], and the miR-132/212
cluster [31, 43, 48]). As Lau et al. have shown [31], fur-
ther work is needed to uncover the pattern of miRNA
levels over the Braak NFT stages with dozens of brain
samples from different cortical regions in each Braak
NFT stage.
Although it remains elusive as to how the upregulation
of hsa-miR-501-3p in the brain has an effect on AD
pathogenesis, our results indicate a possibility that hsa-
miR-501-3p upregulation could cause alterations in the
cell cycle in AD brains. We found that hsa-miR-501-3p
overexpression in cultured cells induced the downregu-
lation of 128 genes that were significantly enriched in
the biological processes of DNA replication and mitotic
cell cycle (Additional file 2: Table S5). Accumulating
evidence indicates that inappropriate cell cycle reentry
in postmitotic neurons, which leads to apoptotic cell
death, is an early sign that precedes the developments of
SPs and NFTs in AD brains [1, 9, 13, 19, 27, 44]. Alter-
natively, Hu et al. [24] have recently demonstrated in rat
brains that miR-501-3p mediates the activity-dependent
regulation of the expression of the AMPA receptor sub-
unit GluA1 in dendrites, suggesting that miR-501-3p
contributes to synaptic plasticity related to cognitive
functions, including learning and memory.
Conclusions
In summary, we discovered that hsa-miR-501-3p is
strongly suggested as a novel serum biomarker for AD.
Our study associated the downregulation of serum hsa-
miR-501-3p levels with its remarkable upregulation in
AD brains, which may be involved in the pathogenesis
of AD through an aberrant neuronal cell cycle. Our
study suggests that serum hsa-miR-501-3p is a novel in-
dicator that presumably reflects the progression of AD.
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